Moore Capital Management Trims AbbVie Stake

Hedge fund reduces position in pharmaceutical company by 40%

Mar. 17, 2026 at 10:52am

Got story updates? Submit your updates here. ›

Moore Capital Management LP reduced its stake in AbbVie Inc. (NYSE:ABBV) by 40.0% during the 3rd quarter, according to the company's most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,000 shares of the company's stock after selling 40,000 shares during the period.

Why it matters

As a major pharmaceutical company, changes in institutional ownership of AbbVie stock can signal shifts in investor sentiment and market expectations for the company's performance.

The details

According to the 13F filing, Moore Capital Management sold 40,000 shares of AbbVie stock in the third quarter, reducing its total position to 60,000 shares. The firm's holdings in AbbVie were valued at $13,892,000 as of the filing.

  • The 13F filing covers the 3rd quarter of the year.

The players

Moore Capital Management LP

A global hedge fund management firm based in New York City.

AbbVie Inc.

A research-driven biopharmaceutical company headquartered in North Chicago, Illinois that focuses on developing therapies for complex and chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Moore Capital Management's AbbVie position could signal some institutional concerns about the pharmaceutical company's outlook, though a single hedge fund's trading activity does not necessarily reflect broader market sentiment.